TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 FINAL #1 Facility: Battelle Columbus Laboratory Chemical CAS #: TEFBINARYMIX Lock Date: 03/27/02 Cage Range: All Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice 25020 Natural Death 25021 Terminal Sacrifice Removal Date Range: All Treatment Groups: Include 001 0 NG / 0 UG Include 002 10 NG / 10 UG Include 003 100 NG /100 UG Include 005 300 NG /300 UG Include 007 1000 NG/1000 UG a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 98 86 98 98 98 Early Deaths Moribund Sacrifice 22 19 24 19 20 Natural Death 8 12 6 10 7 Dosing Accident 1 1 1 2 Survivors Terminal Sacrifice 22 21 22 24 24 Animals Examined Microscopically 53 53 53 53 53 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (53) (53) (52) (53) (52) Cyst 1 (2%) Perforation 1 (2%) 2 (4%) Muscularis, Inflammation 3 (6%) 1 (2%) 1 (2%) 3 (6%) 3 (6%) Periesophageal Tissue, Hemorrhage 1 (2%) Periesophageal Tissue, Inflammation 1 (2%) 1 (2%) Intestine Large, Colon (53) (53) (53) (52) (49) Hyperplasia, Lymphoid 1 (2%) Parasite Metazoan 2 (4%) Intestine Large, Rectum (53) (53) (53) (53) (50) Metaplasia, Squamous 1 (2%) Parasite Metazoan 2 (4%) 1 (2%) 3 (6%) Intestine Large, Cecum (53) (53) (53) (52) (49) Mineralization 1 (2%) Intestine Small, Jejunum (53) (53) (52) (52) (49) Hyperplasia, Lymphoid 1 (2%) 2 (4%) 1 (2%) Ulcer 1 (2%) Intestine Small, Ileum (53) (53) (52) (52) (49) Hyperplasia, Lymphoid 1 (2%) Liver (53) (53) (52) (52) (51) Angiectasis 3 (6%) 1 (2%) 1 (2%) 2 (4%) 5 (10%) Basophilic Focus 9 (17%) 7 (13%) 8 (15%) 2 (4%) 3 (6%) Basophilic Focus, Multiple 13 (25%) 15 (28%) 6 (12%) 1 (2%) 3 (6%) Cholangiofibrosis 1 (2%) 7 (13%) 39 (76%) Clear Cell Focus 3 (6%) 2 (4%) 2 (4%) 3 (6%) 1 (2%) Clear Cell Focus, Multiple 6 (11%) 1 (2%) 1 (2%) Eosinophilic Focus 7 (13%) 8 (15%) 4 (8%) 7 (13%) 1 (2%) Eosinophilic Focus, Multiple 7 (13%) 8 (15%) 26 (50%) 33 (63%) 17 (33%) Fatty Change, Diffuse 3 (6%) 1 (2%) 9 (17%) 31 (60%) 38 (75%) a Number of animals examined microscopically at site and number of animals with lesion Page 2 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - CONT Fatty Change, Focal 3 (6%) 4 (8%) 7 (13%) 1 (2%) 12 (24%) Hematopoietic Cell Proliferation 27 (51%) 29 (55%) 30 (58%) 19 (37%) 11 (22%) Hepatodiaphragmatic Nodule 2 (4%) Hyperplasia, Nodular 2 (4%) 24 (46%) 42 (82%) Inflammation 44 (83%) 41 (77%) 46 (88%) 48 (92%) 46 (90%) Metaplasia 1 (2%) Mixed Cell Focus 7 (13%) 3 (6%) 4 (8%) 2 (4%) 1 (2%) Mixed Cell Focus, Multiple 19 (36%) 19 (36%) 26 (50%) 24 (46%) 2 (4%) Necrosis 4 (8%) 8 (15%) 5 (10%) 4 (8%) 20 (39%) Pigmentation 2 (4%) 5 (9%) 38 (73%) 50 (96%) 50 (98%) Toxic Hepatopathy 2 (4%) 34 (65%) 48 (92%) 49 (96%) Bile Duct, Cyst 4 (8%) 3 (6%) 1 (2%) 5 (10%) 23 (45%) Bile Duct, Dilatation 1 (2%) Bile Duct, Fibrosis 1 (2%) 3 (6%) 3 (6%) 4 (8%) Bile Duct, Hyperplasia 8 (15%) 2 (4%) 9 (17%) 29 (56%) 46 (90%) Centrilobular, Degeneration 5 (9%) 7 (13%) 2 (4%) 4 (8%) 3 (6%) Centrilobular, Fibrosis 1 (2%) 1 (2%) Hepatocyte, Hypertrophy 1 (2%) 7 (13%) 17 (33%) 33 (63%) 50 (98%) Hepatocyte, Multinucleated 14 (27%) 46 (88%) 48 (94%) Oval Cell, Hyperplasia 2 (4%) 2 (4%) 15 (29%) 39 (75%) 46 (90%) Portal, Fibrosis 7 (13%) 34 (67%) Serosa, Inflammation, Chronic Active 1 (2%) Mesentery (47) (47) (46) (47) (42) Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) 2 (4%) 4 (10%) Fat, Necrosis 2 (4%) 2 (4%) 1 (2%) Oral Mucosa (12) (11) (25) (30) (36) Gingival, Hyperplasia, Squamous 8 (67%) 8 (73%) 18 (72%) 22 (73%) 24 (67%) Pharyngeal, Inflammation 1 (3%) Pancreas (53) (53) (52) (52) (50) Inflammation, Chronic Active 3 (6%) 3 (6%) 1 (2%) 4 (8%) Acinus, Atrophy 2 (4%) 1 (2%) 1 (2%) 8 (16%) Acinus, Hyperplasia 2 (4%) 1 (2%) Acinus, Vacuolization Cytoplasmic 7 (13%) 40 (80%) Artery, Inflammation, Chronic Active 1 (2%) 2 (4%) 2 (4%) Duct, Dilatation 1 (2%) Salivary Glands (53) (51) (52) (50) (52) Inflammation, Chronic Active 1 (2%) Stomach, Forestomach (53) (53) (52) (52) (51) Hyperkeratosis 1 (2%) 2 (4%) Hyperplasia, Squamous 1 (2%) 1 (2%) 2 (4%) 7 (13%) 8 (16%) Inflammation 1 (2%) 1 (2%) Mineralization 1 (2%) 1 (2%) Ulcer 1 (2%) 2 (4%) 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 3 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - CONT Stomach, Glandular (53) (53) (52) (52) (51) Cyst 1 (2%) Ectopic Tissue 1 (2%) Erosion 1 (2%) 2 (4%) Inflammation, Chronic Active 1 (2%) Mineralization 4 (8%) 3 (6%) 3 (6%) 1 (2%) Ulcer 1 (2%) Tooth (23) (14) (33) (35) (31) Peridontal Tissue, Inflammation 23 (100%) 14 (100%) 33 (100%) 35 (100%) 31 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (53) (53) (52) (53) (52) Aorta, Mineralization 1 (2%) Heart (53) (52) (52) (53) (52) Cardiomyopathy 22 (42%) 19 (37%) 22 (42%) 26 (49%) 15 (29%) Fibrosis 1 (2%) Hemorrhage 1 (2%) Inflammation, Chronic Active 1 (2%) 1 (2%) Thrombosis 1 (2%) Coronary Artery, Inflammation, Chronic Active 1 (2%) 6 (12%) Pericardium, Necrosis 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (53) (53) (52) (52) (51) Angiectasis 17 (32%) 26 (49%) 33 (63%) 23 (44%) 5 (10%) Atrophy 3 (6%) 35 (69%) Degeneration, Cystic 13 (25%) 12 (23%) 13 (25%) 14 (27%) 16 (31%) Hematopoietic Cell Proliferation 1 (2%) Hyperplasia 11 (21%) 18 (34%) 23 (44%) 25 (48%) 18 (35%) Hypertrophy 47 (89%) 38 (72%) 44 (85%) 41 (79%) 32 (63%) Necrosis 1 (2%) 1 (2%) Vacuolization Cytoplasmic 11 (21%) 12 (23%) 14 (27%) 10 (19%) 13 (25%) Adrenal Medulla (52) (53) (52) (52) (51) Hyperplasia 15 (29%) 13 (25%) 14 (27%) 13 (25%) 3 (6%) Islets, Pancreatic (53) (53) (52) (52) (50) Hyperplasia 1 (2%) Parathyroid Gland (45) (47) (46) (47) (46) Hyperplasia 1 (2%) Pituitary Gland (53) (53) (53) (52) (52) a Number of animals examined microscopically at site and number of animals with lesion Page 4 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM - CONT Angiectasis 17 (32%) 20 (38%) 15 (28%) 17 (33%) 1 (2%) Cyst 1 (2%) 3 (6%) Cytoplasmic Alteration 3 (6%) Inflammation 1 (2%) Vacuolization Cytoplasmic 1 (2%) Pars Distalis, Hyperplasia 13 (25%) 13 (25%) 19 (36%) 20 (38%) 13 (25%) Pars Intermedia, Hyperplasia 2 (4%) Thyroid Gland (53) (53) (51) (52) (52) C-Cell, Hyperplasia 15 (28%) 19 (36%) 22 (43%) 12 (23%) 15 (29%) Follicle, Cyst 2 (4%) Follicular Cell, Hypertrophy 14 (26%) 17 (32%) 34 (67%) 35 (67%) 42 (81%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (53) (53) (53) (53) (50) Inflammation 45 (85%) 49 (92%) 46 (87%) 40 (75%) 23 (46%) Duct, Cyst 38 (72%) 40 (75%) 48 (91%) 43 (81%) 43 (86%) Ovary (53) (53) (52) (52) (49) Atrophy 45 (85%) 44 (83%) 45 (87%) 43 (83%) 16 (33%) Cyst 14 (26%) 7 (13%) 17 (33%) 14 (27%) 13 (27%) Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) Inflammation, Suppurative 1 (2%) Oviduct (1) (1) (2) (3) Cyst 1 (100%) 1 (100%) 2 (100%) Inflammation, Chronic Active 1 (100%) 3 (100%) Uterus (53) (53) (53) (52) (50) Adenomyosis 1 (2%) 1 (2%) Hemorrhage 1 (2%) Hyperplasia 1 (2%) Inflammation, Chronic Active 3 (6%) 1 (2%) 7 (13%) 2 (4%) Inflammation, Suppurative 3 (6%) 5 (9%) 8 (15%) 10 (19%) 5 (10%) Metaplasia, Squamous 27 (51%) 30 (57%) 35 (66%) 36 (69%) 14 (28%) Ulcer 1 (2%) Endometrium, Hyperplasia, Cystic 28 (53%) 23 (43%) 34 (64%) 18 (35%) 12 (24%) Vagina (1) (1) (1) (1) Inflammation 1 (100%) ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion Page 5 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (53) (53) (53) (53) (53) Atrophy 1 (2%) Degeneration 1 (2%) Hyperplasia 39 (74%) 38 (72%) 42 (79%) 48 (91%) 49 (92%) Lymph Node (4) (7) (2) (7) (14) Angiectasis 1 (14%) 1 (7%) Inguinal, Hyperplasia, Plasma Cell 1 (14%) Lumbar, Ectasia 4 (100%) 4 (57%) 1 (14%) Lumbar, Hemorrhage 2 (29%) Lumbar, Hyperplasia 1 (14%) Lumbar, Hyperplasia, Plasma Cell 4 (100%) 1 (14%) Mediastinal, Ectasia 3 (21%) Mediastinal, Hemorrhage 1 (14%) 2 (14%) Mediastinal, Hyperplasia, Histiocytic 1 (14%) 1 (14%) 3 (21%) Mediastinal, Hyperplasia, Lymphoid 1 (14%) Mediastinal, Hyperplasia, Plasma Cell 2 (14%) Pancreatic, Hyperplasia, Histiocytic 1 (14%) 3 (21%) Pancreatic, Hyperplasia, Plasma Cell 1 (7%) Pancreatic, Pigmentation 1 (14%) 1 (7%) Renal, Ectasia 1 (14%) 1 (50%) 1 (14%) 1 (7%) Renal, Hemorrhage 1 (50%) Renal, Hyperplasia, Histiocytic 1 (14%) 2 (14%) Renal, Hyperplasia, Lymphoid 1 (7%) Renal, Hyperplasia, Plasma Cell 1 (14%) 1 (14%) Lymph Node, Mandibular (53) (51) (52) (50) (51) Congestion 1 (2%) Ectasia 3 (6%) 6 (12%) 3 (6%) 6 (12%) Hemorrhage 1 (2%) 1 (2%) Hyperplasia, Lymphoid 1 (2%) 2 (4%) 3 (6%) 2 (4%) 5 (10%) Hyperplasia, Plasma Cell 37 (70%) 37 (73%) 40 (77%) 36 (72%) 31 (61%) Lymph Node, Mesenteric (53) (53) (52) (52) (49) Hemorrhage 1 (2%) Hyperplasia, Histiocytic 1 (2%) 2 (4%) Hyperplasia, Lymphoid 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) Spleen (53) (53) (52) (52) (50) Fibrosis 1 (2%) Hematopoietic Cell Proliferation 51 (96%) 51 (96%) 49 (94%) 47 (90%) 44 (88%) Hyperplasia 1 (2%) Pigmentation 47 (89%) 46 (87%) 43 (83%) 51 (98%) 46 (92%) Lymphoid Follicle, Atrophy 2 (4%) 4 (8%) 5 (10%) a Number of animals examined microscopically at site and number of animals with lesion Page 6 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - CONT Red Pulp, Atrophy 1 (2%) 1 (2%) 5 (10%) Thymus (53) (50) (48) (50) (51) Atrophy 33 (62%) 33 (66%) 43 (90%) 42 (84%) 49 (96%) Cyst 1 (2%) Hemorrhage 1 (2%) 3 (6%) 1 (2%) Hyperplasia, Lymphoid 2 (4%) Inflammation 1 (2%) Epithelial Cell, Hyperplasia 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (53) (53) (52) (53) (52) Cyst 3 (6%) 2 (4%) 2 (4%) 3 (6%) 1 (2%) Hyperplasia 29 (55%) 29 (55%) 25 (48%) 22 (42%) 3 (6%) Inflammation, Granulomatous 5 (9%) 4 (8%) 3 (6%) Duct, Cyst 1 (2%) Skin (53) (53) (53) (53) (53) Angiectasis 1 (2%) Cyst Epithelial Inclusion 1 (2%) Fibrosis 1 (2%) Inflammation 1 (2%) 1 (2%) Ulcer 2 (4%) 1 (2%) Dermis, Fibrosis 1 (2%) Epidermis, Hyperplasia 1 (2%) Subcutaneous Tissue, Inflammation 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (1) (1) (1) (1) Hemorrhage 1 (100%) Inflammation 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (53) (53) (53) (52) (52) Hemorrhage 1 (2%) 1 (2%) Hydrocephalus 1 (2%) ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion Page 7 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (53) (53) (52) (53) (52) Hemorrhage 1 (2%) Infiltration Cellular, Histiocyte 47 (89%) 41 (77%) 47 (90%) 46 (87%) 45 (87%) Inflammation 8 (15%) 5 (9%) 2 (4%) 4 (8%) 1 (2%) Metaplasia, Squamous 1 (2%) 2 (4%) 11 (21%) Mineralization 1 (2%) 1 (2%) Alveolar Epithelium, Hyperplasia 23 (43%) 20 (38%) 17 (33%) 5 (9%) 5 (10%) Alveolar Epithelium, Metaplasia, Bronchiolar 6 (11%) 23 (44%) 34 (64%) 32 (62%) Bronchiole, Hyperplasia 1 (2%) Mediastinum, Hemorrhage 1 (2%) Mediastinum, Necrosis 1 (2%) Serosa, Inflammation 1 (2%) Nose (53) (53) (53) (53) (53) Hyperplasia 1 (2%) Inflammation 22 (42%) 13 (25%) 13 (25%) 13 (25%) 31 (58%) Glands, Hyperplasia 8 (15%) Olfactory Epithelium, Degeneration 1 (2%) 2 (4%) Olfactory Epithelium, Metaplasia 4 (8%) 3 (6%) 5 (9%) 6 (11%) 15 (28%) Respiratory Epithelium, Hyperplasia 10 (19%) 5 (9%) 7 (13%) 11 (21%) 20 (38%) Respiratory Epithelium, Metaplasia 1 (2%) Respiratory Epithelium, Vacuolization Cytoplasmic 1 (2%) Trachea (53) (53) (52) (53) (52) Inflammation 1 (2%) Peritracheal Tissue, Hemorrhage 1 (2%) Peritracheal Tissue, Inflammation 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (53) (53) (53) (52) (52) Anterior Chamber, Ciliary Body, Cornea, Inflammation 1 (2%) 3 (6%) Cornea, Inflammation 1 (2%) Retina, Atrophy 1 (2%) 3 (6%) 4 (8%) 2 (4%) 5 (10%) Harderian Gland (53) (53) (53) (52) (52) Inflammation 20 (38%) 14 (26%) 16 (30%) 14 (27%) 16 (31%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (53) (53) (52) (52) (51) a Number of animals examined microscopically at site and number of animals with lesion Page 8 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:43:49 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM - CONT Accumulation, Hyaline Droplet 2 (4%) 1 (2%) 1 (2%) 1 (2%) Calculus Gross Observation 1 (2%) Calculus Micro Observation Only 7 (13%) 4 (8%) 1 (2%) 4 (8%) 1 (2%) Casts Protein 2 (4%) 1 (2%) Cyst 1 (2%) 1 (2%) 1 (2%) Infarct 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) 1 (2%) Inflammation, Suppurative 5 (9%) 3 (6%) 1 (2%) 5 (10%) 1 (2%) Mineralization 42 (79%) 38 (72%) 39 (75%) 42 (81%) 35 (69%) Necrosis 1 (2%) Nephropathy 29 (55%) 22 (42%) 29 (56%) 34 (65%) 43 (84%) Pigmentation 1 (2%) 3 (6%) 7 (13%) 35 (69%) Pelvis, Dilatation 1 (2%) 2 (4%) 1 (2%) Pelvis, Inflammation 3 (6%) 4 (8%) 3 (6%) 5 (10%) Renal Tubule, Degeneration 1 (2%) 2 (4%) 1 (2%) Transitional Epithelium, Hyperplasia 2 (4%) 2 (4%) 4 (8%) 11 (21%) 6 (12%) Ureter (1) (1) (1) (1) Inflammation 1 (100%) 1 (100%) Mineralization 1 (100%) Transitional Epithelium, Hyperplasia 1 (100%) 1 (100%) Urinary Bladder (53) (53) (53) (52) (50) Inflammation 7 (13%) 8 (15%) 5 (9%) 7 (13%) Transitional Epithelium, Hyperplasia 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 9 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------